Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct of ering on December 10, 2025, to strengthen cash position and support continued commercialization of LYMPHIR CRANFORD, N.J., December 23, 2025 – Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-41534 Citius Oncology, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 99-4362660 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | ...

[Company Overview and Business Update](index=1&type=section&id=Company_Overview_and_Business_Update) Citius Oncology is preparing for the Q4 2025 U.S. commercial launch of FDA-approved LYMPHIR, targeting an underserved CTCL market exceeding $400 million [Business Highlights and LYMPHIR Commercialization](index=1&type=section&id=Business_Highlights_and_LYMPHIR_Commercialization) Citius Oncology is in the final stages of preparing for the U.S. commercial launch of LYMPHIR, planned for the fourth quarter of 2025. This initiative is supported by recent capital raises and established distribution agreements - **LYMPHIR commercial availability** is planned for the **fourth quarter of 2025**[1](index=1&type=chunk)[2](index=2&type=chunk) - Citius Pharmaceuticals raised **$12.5 million** in gross financings during the quarter, with Citius Oncology raising an additional **$9 million** in July 2025, to facilitate LYMPHIR pre-launch initiatives[1](index=1&type=chunk) - The company has secured distribution service agreements with leading global providers and has launch supplies ready[2](index=2&type=chunk) [About Citius Oncology, Inc.](index=2&type=section&id=About_Citius_Oncology_Inc) Citius Oncology is a specialty biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. Its primary asset, LYMPHIR, received FDA approval for relapsed or refractory CTCL, targeting an underserved market estimated to exceed $400 million - Citius Oncology is a specialty biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies[5](index=5&type=chunk) - **LYMPHIR** was approved by the FDA in **August 2024** for the treatment of adults with relapsed or refractory CTCL who had at least one prior systemic therapy[5](index=5&type=chunk) - Management estimates the initial market for LYMPHIR currently exceeds **$400 million**, is growing, and is underserved by existing therapies[5](index=5&type=chunk) [Fiscal Third Quarter 2025 Financial Performance](index=1&type=section&id=Fiscal_Third_Quarter_2025_Financial_Performance) The company reported an increased net loss of $5.4 million for Q3 2025, with significant balance sheet changes including higher inventory and liabilities, and no net cash from operations [Key Financial Highlights](index=1&type=section&id=Key_Financial_Highlights) For the fiscal third quarter ended June 30, 2025, Citius Oncology reported a net loss of $5.4 million, an increase from $4.8 million in the prior year. R&D expenses decreased while G&A and stock-based compensation expenses increased. The company also completed a public offering in July 2025, generating approximately $7.4 million in net proceeds - On July 17, 2025, Citius Oncology completed a public offering generating net proceeds of approximately **$7.4 million**[3](index=3&type=chunk) Fiscal Third Quarter 2025 Financial Highlights (YoY) | Metric | Q3 2025 (USD) | Q3 2024 (USD) | Change (YoY) (USD) | | :----------------------- | :---------- | :---------- | :----------- | | R&D expenses | $938,000 | $1.1 million | ↓ $162,000 | | G&A expenses | $1.9 million | $1.5 million | ↑ $400,000 | | Stock-based compensation | $2.1 million | $2.0 million | ↑ $100,000 | | Net loss | $(5.4) million | $(4.8) million | ↑ $(0.6) million | | Net loss per share | $(0.08) | $(0.07) | ↑ $(0.01) | - As of June 30, 2025, the Company had **$112** in cash and cash equivalents and **71,552,402** common shares outstanding[3](index=3&type=chunk) [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed_Consolidated_Balance_Sheets) As of June 30, 2025, Citius Oncology's total assets increased to $91.7 million from $84.4 million at September 30, 2024, primarily driven by a significant increase in inventory. Total liabilities also rose substantially, leading to a decrease in total stockholders' equity Condensed Consolidated Balance Sheets Summary | Metric | June 30, 2025 (USD) | September 30, 2024 (USD) | Change (USD) | | :-------------------------- | :---------------- | :------------------- | :----- | | Total Current Assets | $18,309,079 | $10,968,878 | ↑ $7,340,201 | | Total Assets | $91,709,079 | $84,368,878 | ↑ $7,340,201 | | Total Current Liabilities | $52,990,335 | $32,700,428 | ↑ $20,289,907 | | Total Liabilities | $59,311,166 | $38,228,539 | ↑ $21,082,627 | | Total Stockholders' Equity | $32,397,913 | $46,140,339 | ↓ $13,742,426 | - Inventory increased significantly from **$8,268,766** at September 30, 2024, to **$17,208,967** at June 30, 2025[9](index=9&type=chunk) - Accounts payable increased from **$3,711,622** to **$8,667,419**, and accrued expenses rose from **$0** to **$8,458,554**[9](index=9&type=chunk) [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed_Consolidated_Statements_of_Operations) For the three months ended June 30, 2025, Citius Oncology reported a net loss of $5.37 million, an increase from $4.77 million in the prior year, primarily due to higher general and administrative expenses and the introduction of interest expense. For the nine-month period, the net loss widened to $19.76 million Statements of Operations (Three Months Ended June 30) | Metric | 2025 (USD) | 2024 (USD) | Change (USD) | | :-------------------------- | :---------- | :---------- | :----- | | Revenues | $0 | $0 | No change | | Research and development | $938,277 | $1,131,439 | ↓ $193,162 | | General and administrative | $1,881,447 | $1,540,411 | ↑ $341,036 | | Total Operating Expenses | $4,944,961 | $4,628,850 | ↑ $316,111 | | Operating Loss | $(4,944,961) | $(4,628,850) | ↑ $(316,111) | | Interest expense | $160,755 | $0 | New expense | | Net Loss | $(5,369,956) | $(4,772,850) | ↑ $(597,106) | | Net Loss Per Share | $(0.08) | $(0.07) | ↑ $(0.01) | Statements of Operations (Nine Months Ended June 30) | Metric | 2025 (USD) | 2024 (USD) | Change (USD) | | :-------------------------- | :------------ | :------------ | :----- | | Research and development | $5,342,198 | $3,628,900 | ↑ $1,713,298 | | General and administrative | $7,446,753 | $4,443,899 | ↑ $3,002,854 | | Total Operating Expenses | $18,811,238 | $13,903,799 | ↑ $4,907,439 | | Net Loss | $(19,764,713) | $(14,335,799) | ↑ $(5,428,914) | | Net Loss Per Share | $(0.28) | $(0.21) | ↑ $(0.07) | - Stock-based compensation included in general and administrative expenses was **$2,125,237** for Q3 2025 and **$6,022,287** for the nine months ended June 30, 2025[11](index=11&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=5&type=section&id=Condensed_Consolidated_Statements_of_Cash_Flows) For the nine months ended June 30, 2025, Citius Oncology reported no net cash provided by operating activities, despite a net loss of $19.76 million. This was influenced by non-cash adjustments like stock-based compensation and significant changes in operating assets and liabilities, particularly an increase in inventory and accrued expenses - Net loss for the nine months ended June 30, 2025, was **$(19,764,713)**[13](index=13&type=chunk) Key Adjustments to Net Loss for Cash Flow (Nine Months Ended June 30) | Adjustment | 2025 (USD) | 2024 (USD) | | :-------------------------- | :----------- | :----------- | | Stock-based compensation expense | $6,022,287 | $5,831,000 | | Deferred income tax expense | $792,720 | $432,000 | | Inventory | $(8,940,201) | $0 | | Prepaid expenses | $1,600,000 | $(2,271,920) | | Accounts payable | $4,955,797 | $(1,289,045) | | Accrued expenses | $8,458,554 | $185,930 | | Due to related party | $6,875,556 | $11,447,834 | - Net Cash Provided By Operating Activities was **$0** for both the nine months ended June 30, 2025, and 2024[13](index=13&type=chunk) [Forward-Looking Statements and Risks](index=2&type=section&id=Forward_Looking_Statements_and_Risks) This section highlights substantial risks, including the need for additional funding, challenges in LYMPHIR commercialization, and compliance with regulatory and market standards [Forward-Looking Statements and Risks](index=2&type=section&id=Forward_Looking_Statements_and_Risks_Details) This section outlines various forward-looking statements and significant risks that could impact Citius Oncology's future performance. Key risks include the need for substantial additional funding, challenges in commercializing LYMPHIR, maintaining financing agreements, market acceptance, Nasdaq compliance, supply chain dependencies, intellectual property matters, and regulatory and competitive pressures - Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect business, operating results, financial condition, and stock price[6](index=6&type=chunk) - Key risks include the need for substantial additional funds to fund operations beyond **September 2025** and for at least the next **12 months** as a going concern[6](index=6&type=chunk) - Other significant risks involve the ability to commercialize LYMPHIR, obtain and maintain financing and strategic agreements, market acceptance, compliance with Nasdaq listing standards, dependence on third-party suppliers, intellectual property matters, government regulation, and competition[6](index=6&type=chunk) [Investor Information](index=2&type=section&id=Investor_Information) This section provides essential contact details for investor and media inquiries [Contact Information](index=2&type=section&id=Contact_Information) This section provides contact details for investor and media inquiries - Investor Contact: Ilanit Allen at ir@citiuspharma.com or **908-967-6677 x113**[7](index=7&type=chunk) - Media Contact: Greg Salsburg at Greg@STiR-communications.com[7](index=7&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Citius Oncology, Inc. (Exact name of registrant as specified in its charter) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41534 FORM 10-Q (Mark One) | Delaware | 99 ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the transition period from ______________ to ______________ Commission File Number 001-41534 Citius Oncology, Inc. (Exact name of registrant as specified in its charter) | Delaware | 9 ...

Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update CRANFORD, N.J., May 14, 2025 -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025. "In Q2 2025, Citius Oncology advanced its transformation from a d ...

CRANFORD, N.J., December 27, 2024 -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024. - Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024, following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane ...

The Company is responsible for preparing, filing, prosecuting, and maintaining all patent applications and patents included in the licensed patents that we intend to pursue within the territory. Obligations to Dr. Reddy's under the Asset Purchase Agreement 10 Also under the agreement with Dr. Reddy's, the Company is required to (i) use commercially reasonable efforts to make commercially available products in the CTCL indication, peripheral T-cell lymphoma indication and immuno-oncology indication, (ii) ini ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41534 TenX Keane Acquisition (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State or other jurisdiction of inco ...

Company Formation and IPO - The company was incorporated on March 1, 2021, in the Cayman Islands for the purpose of entering into a business combination, initially focusing on Asia but excluding entities headquartered in China[23]. - The company completed its IPO on October 18, 2022, issuing 6,600,000 units at $10.00 per unit, generating total gross proceeds of $66,000,000[26]. - A total of $67,320,000 from the IPO and private placement was placed in a U.S.-based trust account for the benefit of public shareholders[28]. - The company completed its IPO on October 18, 2022, raising gross proceeds of $66 million from the sale of 6,600,000 Units[118]. - A Private Placement of 394,000 Placement Units generated total proceeds of $3.94 million at a price of $10.00 per Unit[119]. Financial Performance and Projections - The company has had no revenue since inception and has incurred losses due to formation and operating costs, relying on securities sales and loans for funding[31]. - For the year ended December 31, 2023, the company reported a net income of $2,419,304, primarily from investment income on trust assets amounting to $3,432,374, offset by operating expenses of $1,013,070[116]. - The company has not generated any operating revenues to date and will not do so until the completion of its initial business combination[115]. - The company incurred increased expenses of $1,013,070 due to being a public company, including legal, financial reporting, and auditing compliance costs[115]. - The company expects primary liquidity requirements of $92,000 for legal and accounting expenses and $216,800 for working capital from December 31, 2023, until the business combination[125]. - The company incurred a cash decrease of $256,429 for the year ended December 31, 2023, with cash used in operating activities of $601,304 and cash provided by financing activities of $1,664,875[131]. - The company has less than 12 months to complete a business combination, or it must liquidate and redeem Public Shares[130]. - The company has no long-term debt obligations or capital lease obligations[132]. - The company is targeting larger businesses than it can acquire with the net proceeds from the IPO, potentially requiring additional financing[127]. Business Combination and Strategy - The company extended the deadline to complete an initial business combination to January 18, 2024, by depositing $660,000 into the trust account[34]. - The company has the option to extend the business combination period up to eight times, with specific deposit amounts required for each extension[35]. - The company intends to focus on acquiring private companies in Asia, with a total enterprise value between $200 million and $600 million[49]. - The company aims to provide target businesses with an alternative to traditional IPOs, which may be less expensive and offer greater certainty of execution[46]. - The merger agreement with Citius Oncology is expected to be completed in the first half of 2024, pending shareholder approval and regulatory conditions[59]. - Upon closing the merger, Citius Pharma will receive 67.5 million shares of the combined company, valued at $675 million based on an implied share price of $10.00[66]. - The company plans to structure its initial business combination to acquire 100% of the equity interests or assets of the target business[61]. - The company will redeem 100% of outstanding public shares at approximately $10.99 per share if it cannot complete the initial business combination within the specified time[60]. - The company aims to acquire businesses with strong management teams and significant revenue and earnings growth potential[54]. - The company will only pursue business combinations that will benefit from being publicly traded and can effectively utilize access to broader capital sources[63]. - The Holding Foreign Companies Accountable Act may impact the company's ability to complete certain business combinations due to regulatory oversight[70]. Management and Governance - The management team has extensive experience in mergers and acquisitions, with a strong track record in identifying acquisition opportunities[45]. - The management team includes experienced professionals from various sectors, enhancing the company's ability to identify attractive acquisition opportunities[48]. - The company has maintained its principal executive office in New York, NY, with a monthly cost of $10,000 for office space and related services[87]. - The company currently has 2 officers and does not intend to hire full-time employees before completing its initial business combination[89]. - The company does not intend to ensure that management maintains their positions post-initial business combination, although some may negotiate to stay[177]. - No cash compensation has been provided to officers or directors, but $10,000 per month will be paid for office space and administrative services[176]. - The board of directors is composed of five members, with each director serving a two-year term[173]. - The company has established an audit committee, which is required to be comprised solely of independent directors under Nasdaq rules[178]. - The independent directors will hold regularly scheduled meetings to ensure compliance with SEC and Nasdaq rules[175]. - The company has established an audit committee to oversee independent auditors and ensure compliance with regulations[185]. - The compensation committee is responsible for reviewing and approving the CEO's compensation and evaluating performance based on corporate goals[186]. - The company has not established specific minimum qualifications for director nominees but considers various factors such as educational background and professional experience[192]. - Directors and officers have fiduciary duties under Cayman Islands law, including acting in the best interests of the company and avoiding conflicts of interest[196]. - The company will indemnify its officers and directors to the maximum extent permitted by law, including for liabilities incurred in their capacities[207]. - The compensation committee may retain external advisers and will consider their independence before engagement[189]. - The board will consider director candidates recommended by shareholders during the nomination process for the annual meeting[191]. - The company intends to disclose any amendments to its Code of Ethics in a Current Report on Form 8-K[194]. Shareholder Information - The total number of Ordinary Shares issued and outstanding is 6,653,077[220]. - 10XYZ Holdings LP, Xiaofeng Yuan, and Taylor Zhang each own 2,044,000 Ordinary Shares, representing approximately 30.7% of the outstanding shares[221]. - All executive officers and directors as a group (5 individuals) collectively own 2,044,000 Ordinary Shares, which is 30.7% of the total[221]. - Hudson Bay Capital Management LP holds 500,000 Ordinary Shares, accounting for 7.5% of the outstanding shares[221]. - Wolverine Asset Management, LLC owns 566,713 Ordinary Shares, representing 8.5% of the total[221]. - Mizuho Financial Group, Inc. has 522,030 Ordinary Shares, which is 7.8% of the outstanding shares[221]. - The beneficial ownership interests consist of Founder Shares and Private Placement Shares[222]. Internal Controls and Compliance - A material weakness in internal control over financial reporting was identified as of December 31, 2023, which may adversely affect the accuracy and timeliness of financial reporting[156]. - Disclosure controls and procedures were deemed ineffective due to material weaknesses related to accounting for accruals and complex financial instruments[151]. - Management is assessing resource needs and roles, particularly in accounting and financial reporting, to address identified weaknesses[152]. - The company has not made any changes in internal control over financial reporting during the fiscal quarter ended December 31, 2023, that materially affected its effectiveness[159]. - The audit committee consists of independent directors, with Cathy Jiang qualifying as an "audit committee financial expert" as defined by SEC rules[179]. - The company has applied for a tax exemption from the Cayman Islands government, which would exempt it from taxes on profits for a period of 20 years[86]. - The company is classified as an "emerging growth company" and is eligible for certain exemptions from reporting requirements, including not being required to comply with auditor attestation requirements[82]. - The company has not paid any cash dividends to date and does not intend to do so prior to completing its initial business combination[102]. - The company has not identified any significant cybersecurity threats that could materially affect its business strategy or financial condition[93].